Risk factors for cholangiocarcinoma

Hepatology

Volumn 54, Issue 1, 2011, Pages 173-184

  Tyson, Gia L ^a   El Serag, Hashem B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; THORIUM DIOXIDE;

ALCOHOL CONSUMPTION; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT CYST; BILE DUCT STONE; CANCER CLASSIFICATION; CANCER RISK; CHOLANGITIS; CLONORCHIASIS; CLONORCHIS SINENSIS; COMMON BILE DUCT STONE; DIABETES MELLITUS; ENTERITIS; GENETIC POLYMORPHISM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; OBESITY; OPISTHORCHIASIS; OPISTHORCHIS VIVERRINI; PARASITOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CHOLEDOCHAL CYST; HUMANS; PARASITIC DISEASES; RISK FACTORS;

EID: 79959572626     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24351     Document Type: Article

References (63)

1. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42: 253-260.
2. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 33-42.
3. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125.
4. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008; 12: 131-150.
5. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 2008; 24: 349-356.
6. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82.
7. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. HEPATOLOGY 2001; 33: 1353-1357.
8. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
9. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820.
10. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-875.
11. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. 2011. .
12. Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Sripa B. Opisthorchis viverrini: the carcinogenic human liver fluke. World J Gastroenterol 2008; 14: 666-674.
13. Upatham ES, Viyanant V. Opisthorchis viverrini and opisthorchiasis: a historical review and future perspective. Acta Trop 2003; 88: 171-176.
14. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci 2010; 25: 1011-1016.
15. Parkin DM, Srivatanakul P, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991; 48: 323-328.
16. Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer 2005; 117: 854-860.
17. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25: 933-940.
18. Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Matsukawa M. Origin of the long common channel based on pancreatographic findings in pancreaticobiliary maljunction. Dig Liver Dis 2005; 37: 363-367.
19. Mabrut JY, Bozio G, Hubert C, Gigot JF. Management of congenital bile duct cysts. Dig Surg 2010; 27: 12-18.
20. Soreide K, Korner H, Havnen J, Soreide JA. Bile duct cysts in adults. Br J Surg 2004; 91: 1538-1548.
21. Edil BH, Cameron JL, Reddy S, Lum Y, Lipsett PA, Nathan H, et al. Choledochal cyst disease in children and adults: a 30-year single-institution experience. J Am Coll Surg 2008; 206: 1000-1005.
22. Kobayashi S, Asano T, Yamasaki M, Kenmochi T, Nakagohri T, Ochiai T. Risk of bile duct carcinogenesis after excision of extrahepatic bile ducts in pancreaticobiliary maljunction. Surgery 1999; 126: 939-944.
23. Yamaguchi M. Congenital choledochal cyst. Analysis of 1, 433 patients in the Japanese literature. Am J Surg 1980; 140: 653-657.
24. Todani T, Watanabe Y, Toki A, Urushihara N. Carcinoma related to choledochal cysts with internal drainage operations. Surg Gynecol Obstet 1987; 164: 61-64.
25. Watanabe Y, Toki A, Todani T. Bile duct cancer developed after cyst excision for choledochal cyst. J Hepatobiliary Pancreat Surg 1999; 6: 207-212.
26. Voyles CR, Smadja C, Shands WC, Blumgart LH. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg 1983; 118: 986-988.
27. Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008; 103: 1716-1720.
28. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228.
29. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-164.
30. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary sclerosing cholangitis: summary of a workshop. HEPATOLOGY 2006; 44: 746-764.
31. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008; 48: 939-944.
32. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. HEPATOLOGY 2010; 52: 571-577.
33. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-526.
34. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-1211.
35. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997; 32: 1042-1045.
36. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. HEPATOLOGY 1998; 27: 311-316.
37. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. HEPATOLOGY 2000; 31: 7-11.
38. Kubo S, Kinoshita H, Hirohashi K, Hamba H. Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995; 19: 637-641.
39. Lesurtel M, Regimbeau JM, Farges O, Colombat M, Sauvanet A, Belghiti J. Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries. Eur J Gastroenterol Hepatol 2002; 14: 1025-1027.
40. Huang MH, Chen CH, Yen CM, Yang JC, Yang CC, Yeh YH, et al. Relation of hepatolithiasis to helminthic infestation. J Gastroenterol Hepatol 2005; 20: 141-146.
41. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14: 632-635.
42. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Contr 2001; 12: 959-964.
43. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg 2002; 195: 713-718.
44. Kato I, Kido C. Increased risk of death in thorotrast-exposed patients during the late follow-up period. Jpn J Cancer Res 1987; 78: 1187-1192.
45. Andersson M, Vyberg M, Visfeldt J, Carstensen B, Storm HH. Primary liver tumors among Danish patients exposed to Thorotrast. Radiat Res 1994; 137: 262-273.
46. van Kaick G, Wesch H, Luhrs H, Liebermann D, Kaul A. Neoplastic diseases induced by chronic alpha-irradiation-epidemiological, biophysical, and clinical results of the German Thorotrast Study. J Radiat Res (Tokyo) 1991; 32( Suppl 2): 20-33.
47. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626.
48. Welzel TM, Mellemkjaer L, Gloria G, Sakoda LC, Hsing AW, El Ghormli L, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007; 120: 638-641.
49. Erichsen R, Jepsen P, Vilstrup H, Ekbom A, Sorensen HT. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol 2009; 24: 513-520.
50. Torbenson M, Yeh MM, Abraham SC. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. Am J Surg Pathol 2007; 31: 1410-1413.
51. Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95: 592-595.
52. Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjaer L, Linet M, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. HEPATOLOGY 1998; 28: 921-925.
53. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-1021.
54. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. HEPATOLOGY 2009; 49: 116-123.
55. Songsivilai S, Dharakul T, Kanistanon D. Hepatitis C virus genotypes in patients with hepatocellular carcinoma and cholangiocarcinoma in Thailand. Trans R Soc Trop Med Hyg 1996; 90: 505-507.
56. Grainge MJ, West J, Solaymani-Dodaran M, Aithal GP, Card TR. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 2009; 100: 178-180.
57. Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 2009; 80: 36-39.
58. Huang WY, Gao YT, Rashid A, Sakoda LC, Deng J, Shen MC, et al. Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China. Carcinogenesis 2008; 29: 100-105.
59. Ko KH, Kim NK, Yim DJ, Hong SP, Park PW, Rim KS, et al. Polymorphisms of 5, 10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population. Anticancer Res 2006; 26: 4229-4233.
60. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S. Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett 2006; 236: 276-281.
61. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. HEPATOLOGY 2008; 47: 90-96.
62. Prawan A, Kukongviriyapan V, Tassaneeyakul W, Pairojkul C, Bhudhisawasdi V. Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. Eur J Cancer Prev 2005; 14: 245-250.
63. Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 2006; 27: 1251-1256.